**November 4, 2025 — Leads & Copy —** Tempus AI, Inc. (NASDAQ: TEM) reported its financial results for the quarter ended September 30, 2025, showcasing significant revenue and profit growth driven by its AI-powered precision medicine solutions. Revenue increased by 84.7% year-over-year, reaching $334.2 million, while gross profit rose by 98.4% to $209.9 million. The company also increased its full-year 2025 revenue guidance to $1.265 billion, representing approximately 80% growth. Tempus ended the quarter with $764.3 million in cash and marketable securities.
Key highlights include a 33% year-over-year increase in clinical tests delivered, driven by oncology and hereditary testing, and $150 million in Insights bookings. Recent operational achievements include the acquisition of Paige, FDA clearances for xR IVD and Tempus Pixel, and an expanded collaboration with Northwestern Medicine.
“Not only are we growing at an incredible rate, reaching positive adjusted EBITDA marks an important milestone and reflects the strength of our underlying business,” said Eric Lefkofsky, Founder and CEO of Tempus.
For more information, visit Tempus’ investor relations site at investors.tempus.com. A conference call and webcast to discuss the results will be held today at 4:30 p.m. Eastern Time, details can be found at https://edge.media-server.com/mmc/p/vg3azega.
Source: Tempus AI, Inc.
